Evidence map›Paper›PMID 26111920›Full record

Trial reportBMC cancer2015

Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlands.

Evelyne M J Meys, Iris J G Rutten, Roy F P M Kruitwagen, Brigitte F Slangen, Martin G M Bergmans, Helen J M M Mertens, Ernst Nolting, Dieuwke Boskamp, Regina G H Beets-Tan, Toon van Gorp

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02218502 (Regional Study Into the Performance and Cost-effectiveness of Simple Ultrasound-based Rules Compared to the Currently Used Risk of Malignancy Index in the Diagnosis of Ovarian Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
4.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02218502 naterminatednot on this map

Regional Study Into the Performance and Cost-effectiveness of Simple Ultrasound-based Rules Compared to the Currently Used Risk of Malignancy Index in the Diagnosis of Ovarian Cancer

TypeinterventionalSponsorMaastricht University Medical CenterRan2014 to 2015Enrolled50ConditionsOvarian Carcinoma, Ovarian Cancer, Ovarian Mass, Ovarian CystArmsUltrasound by general gynaecologist, Ultrasound by an expert ultrasonographist, DW-MRI, Give blood sample
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Evelyne M J MeysDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre (MUMC+), P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands. evelyne.meys@mumc.nl.
Iris J G RuttenDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre (MUMC+), P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands. iris.rutten@mumc.nl.
Roy F P M KruitwagenDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre (MUMC+), P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands. r.kruitwagen@mumc.nl.
Brigitte F SlangenDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre (MUMC+), P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands. brigitte.slangen@mumc.nl.
Martin G M BergmansDepartment of Obstetrics and Gynecology, Laurentius Ziekenhuis Roermond, Mgr. Driessenstraat 6, PO Box 920, , 6040 AX, Roermond, The Netherlands. m.bergmans2@lzr.nl.
Helen J M M MertensDepartment of Obstetrics and Gynecology, Orbis Medical Centre Sittard, Dr. H. van der Hoffplein 1, PO Box 5500, , 6130 MB, Sittard, The Netherlands. h.mertens@orbisconcern.nl.
Ernst NoltingDepartment of Obstetrics and Gynecology, St. Jans Gasthuis Weert, Vogelsbleek 5, PO Box 29, , 6000 AA, Weert, The Netherlands. e.nolting@sjgweert.nl.
Dieuwke BoskampDepartment of Obstetrics and Gynecology, VieCuri Venlo, Tegelseweg 210, PO Box 1926, , 5900 BX, Venlo, The Netherlands. dboskamp@viecuri.nl.
Regina G H Beets-TanGROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC+), P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands. r.beets.tan@mumc.nl.
Toon van GorpDepartment of Obstetrics and Gynecology, Maastricht University Medical Centre (MUMC+), P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands. toon.van.gorp@mumc.nl.
Maastricht University Medical Centre · NLLaurentius Ziekenhuis · NLSt.Jans Gasthuis Weert · NLVieCuri Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEstimating the risk of malignancy is essential in the management of adnexal masses. An accurate differential diagnosis between benign and malignant masses will reduce morbidity and costs due to unnecessary operations, and will improve referral to a gynecologic oncologist for specialized cancer care, which improves outcome and overall survival. The Risk of Malignancy Index is currently the most commonly used method in clinical practice, but has a relatively low diagnostic accuracy (sensitivity 75-80% and specificity 85-90%). Recent reports show that other methods, such as simple ultrasound-based rules, subjective assessment and (Diffusion Weighted) Magnetic Resonance Imaging might be superior to the RMI in the pre-operative differentiation of adnexal masses. METHODS/

designA prospective multicenter cohort study will be performed in the south of The Netherlands. A total of 270 women diagnosed with at least one pelvic mass that is suspected to be of ovarian origin who will undergo surgery, will be enrolled. We will apply the Risk of Malignancy Index with a cut-off value of 200 and a two-step triage test consisting of simple ultrasound-based rules supplemented -if necessary- with either subjective assessment by an expert sonographer or Magnetic Resonance Imaging with diffusion weighted sequences, to characterize the adnexal masses. The histological diagnosis will be the reference standard. Diagnostic performances will be expressed as sensitivity, specificity, positive and negative predictive values and likelihood ratios. DISCUSSION: We hypothesize that this two-step triage test, including the simple ultrasound-based rules, will have better diagnostic accuracy than the Risk of Malignancy Index and therefore will improve the management of women with adnexal masses. Furthermore, we expect this two-step test to be more cost-effective. If the hypothesis is confirmed, the results of this study could have major effects on current guidelines and implementation of the triage test in daily clinical practice could be a possibility.

trial registrationClinicalTrials.gov: registration number NCT02218502.

Indexed as

Cost-Benefit AnalysisOvarian NeoplasmsAdultFemaleHumansMagnetic Resonance ImagingNetherlandsProspective StudiesResearch DesignRiskUltrasonographyYoung Adult

Identifiers

PMID26111920
PMCPMC4489120
OpenAlexW1606812764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.